StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD)

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, Maxim Group decreased their price objective on shares of Aethlon Medical from $11.00 to $4.00 in a report on Tuesday, February 15th.

Shares of Aethlon Medical stock opened at $1.17 on Thursday. Aethlon Medical has a 52-week low of $1.06 and a 52-week high of $12.49. The stock has a market capitalization of $18.03 million, a price-to-earnings ratio of -1.95 and a beta of 0.81. The company has a fifty day moving average of $1.30 and a 200-day moving average of $1.91.

Aethlon Medical (NASDAQ:AEMD – Get Rating) last announced its quarterly earnings results on Monday, February 14th. The medical equipment provider reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.26 million. Aethlon Medical had a negative net margin of 2,823.49% and a negative return on equity of 45.91%. During the same period in the previous year, the company earned ($0.20) EPS. On average, analysts predict that Aethlon Medical will post -0.58 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in shares of Aethlon Medical by 771.7% during the 3rd quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock valued at $282,000 after acquiring an additional 64,691 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Aethlon Medical by 32.3% during the 3rd quarter. Geode Capital Management LLC now owns 136,451 shares of the medical equipment provider’s stock valued at $526,000 after acquiring an additional 33,330 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Aethlon Medical in the third quarter worth approximately $196,000. Dimensional Fund Advisors LP purchased a new position in shares of Aethlon Medical in the third quarter worth approximately $397,000. Finally, Jane Street Group LLC purchased a new position in shares of Aethlon Medical in the third quarter worth approximately $101,000. 10.58% of the stock is currently owned by institutional investors.

About Aethlon Medical (Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Featured Stories